Jul 1 |
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
|
Jun 3 |
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
|
May 30 |
Poseida Therapeutics Partners With Astellas: Worth Watching For Now
|
May 14 |
Poseida Therapeutics GAAP EPS of -$0.25, revenue of $28.14M
|
May 14 |
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
|
May 9 |
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
|
May 3 |
Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
|
May 2 |
Xyphos and Poseida to develop allogeneic cell therapies for cancer
|
May 1 |
Poseida gains on cell therapy pact with Astellas
|
May 1 |
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
|